Optimization of an imaging protocol for stage I seminoma surveillance based on variations in relapse location over time.

Authors

null

Andrew McPartlin

Princess Margaret Cancer Centre, Toronto, ON, Canada

Andrew McPartlin , Ali Hosni , Philippe L. Bedard , Aaron Richard Hansen , Michael A.S. Jewett , Robert James Hamilton , Martin O'Malley , Joan Sweet , Padraig Richard Warde , Peter W. M. Chung

Organizations

Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Research Funding

No funding sources reported

Background: Surveillance is recommended for patients with stage I seminoma post orchidectomy but CT imaging involves ionising radiation, with risk of associated secondary malignancies. We assessed site of disease relapse during surveillance to guide development of a risk adapted imaging protocol. Methods: Data was obtained from a prospectively maintained database of patients with stage I seminoma on surveillance after orchidectomy from 1981-2011. Relapse was determined by clinical and/or radiographic finding with or without pathological confirmation or tumour marker elevation. Results: 753 patients were identified. The median age at orchidectomy was 33.7 years. With a median follow up of 10.5 years, range 1.1-30.1, 115 (15.3%) patients relapsed. Relapse was detected radiologically in 114 (99.1%), with 9 (7.8%) having simultaneously elevated tumour markers. A clinical diagnosis of relapse was made in 1 case (inguinal node – 0.9%). The location and time to relapse are shown in table. Conclusions: In stage I seminoma surveillance, pelvic nodal relapse was restricted to the early period of follow up. Excluding the pelvis during CT imaging after the third year of surveillance may optimise the detection of relapse whilst minimising total radiation exposure. This has now been adopted at our centre since 2011 without any subsequent late pelvic relapses.

Time and location of relapse.

Time of
relapse
Number of
relapses (%)
Location of nodal relapse
InguinalPelvicPAInguinal
and PA
Inguinal
and
mediastinal
Pelvic
and PA
PA and
Mediastinal
nodes
Year 152 (45.2)13412131
Year 234 (29.6)11293
Year313 (11.2)1102
Year 4-58 (7.0)8
Year 6-97 (6.1)7
Year >91 (0.9)1

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Penile, Urethral, and Testicular Cancers

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 475)

DOI

10.1200/jco.2016.34.2_suppl.475

Abstract #

475

Poster Bd #

K22

Abstract Disclosures

Similar Abstracts

First Author: Robert A Huddart

Abstract

2024 ASCO Genitourinary Cancers Symposium

Association of DAZL expression with risk of recurrence in clinical stage 1 testicular germ cell tumors.

First Author: Alok Tewari

Abstract

2023 ASCO Genitourinary Cancers Symposium

A multicenter prospective validation study of the 3-cm cut-off in stage I seminoma (S3MI-PT).

First Author: Mario Fontes-Sousa